




## Product Data Sheet

**Product Name:** Olanzapine  
**CAS No.:** 132539-06-1  
**Cat. No.:** CS-1114  
**Structure**



**MWt:** 312.43  
**Formula:** C<sub>17</sub>H<sub>20</sub>N<sub>4</sub>S  
**Solubility:** DMSO 100 mg/ml 1eq. HCl 100 mg/ml  
**Purity :** >98%

### Biological Activity:

Olanzapine is a thienobenzodiazepine that blocks especially the serotonin (5-hydroxytryptamine [5-HT]) 5-HT<sub>2A</sub> and the dopamine D<sub>2</sub> receptors (K<sub>i</sub> values are 4 and 11 nM respectively) as well as muscarinic (M<sub>1</sub>), histamine (H<sub>1</sub>), 5-HT<sub>2C</sub>, 5-HT<sub>3</sub> to 5-HT<sub>6</sub>, adrenergic (α<sub>1</sub>), and D<sub>4</sub> receptors. Atypical antipsychotic for the treatment of schizophrenia. Olanzapine displays anticholinergic properties.

### References:

- [1]. Cipriani A, Rendell JM, Geddes J. Olanzapine in long-term treatment for bipolar disorder. *Cochrane Database Syst Rev.* 2009 Jan 21;(1):CD004367. doi: 10.1002/14651858.
- [2]. Meera Narasimhan, Travis O Bruce, and Prakash Masand. Review of olanzapine in the management of bipolar disorders. *Neuropsychiatr Dis Treat.* 2007 October; 3(5): 579-587.
- [3]. Vieta E. Olanzapine in bipolar disorder. *Expert Opin Pharmacother.* 2004 Jul;5(7):1613-9.
- [4]. Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. *Neuropsychopharmacology.* 1996 Feb;14(2):87-96.
- [5]. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. *J Pharmacol Exp Ther.* 1992 Aug;262(2):545-51.

...

**Caution: Not fully tested. For research purposes only**

**ChemScene, LLC**